Latest revenue
$0
as of 2025-09-30
Latest net income
$-41.4M
as of 2025-09-30
Net margin
—
as of 2025-09-30
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Biological Products, (No Diagnostic Substances) (165 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Community sentiment
Where do you think ALLO is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $397.9M
- Enterprise value
- $507.2M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 1.43×
- Dividend yield
- 0.0%
- 52-wk high
- $4.46
- 52-wk low
- $0.98
- Beta
- —
- Shares out
- 212.2M
5-year trend
What this company does
PART I Item 1. Business Overview We are a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. We are developing a pipeline of “off-the-shelf” T cell product candidates that are designed to target and kill cancer cells in patients or eliminate pathogenic autoreactive cells in patients with autoimmune disorders. Our engineered T cells are allogeneic, meaning they are derived from healthy donors for intended use in any patient, rather than from an individual patient for that patient’s use, as in the case of autologous T cells. We believe this key difference will…
AI summary unavailable — showing raw filing excerpt
Generated from ALLO's filing dated 2026-03-12
Key risks
Table of Contents Item 1A. Risk Factors RISK FACTORS An investment in shares of our common stock involves a high degree of risk. We have identified the following material factors that make an investment in our common stock speculative or risky. You should carefully consider the following risk factors, as well as the other information in this Annual Report. The occurrence of any of the following risks could harm our business, financial condition, results of operations and growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this Annual Report and those we may make from time to time. The risks described below are…
AI summary unavailable — showing raw filing excerpt
Generated from ALLO's filing dated 2026-03-12
Profitability
Operating margin
-1241813.6%
260.0%Net margin
-1170863.6%
239.9%Return on equity
-65.3%
29.8%Return on assets
-45.9%
2.2%Leverage
Debt / equity
0.42×
492.2%Debt / assets
29.7%
346.2%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-42.6M | +28.7% | — |
Q4 2025 2025-12-31 | — | — | $-38.8M | +35.3% | — |
Q3 2025 2025-09-30 | $0 | — | $-41.4M | +37.5% | — |
Q2 2025 2025-06-30 | $0 | — | $-50.9M | +23.2% | — |
Q1 2025 2025-03-31 | $0 | -100.0% | $-59.7M | +8.1% | — |
Q4 2024 2024-12-31 | $0 | — | $-59.9M | — | — |
Q3 2024 2024-09-30 | $0 | -100.0% | $-66.3M | -8.1% | — |
Q2 2024 2024-06-30 | $0 | -100.0% | $-66.4M | +14.9% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Biological Products, (No Diagnostic Substances) · SIC 2836
Your notes
Keep private notes on ALLO — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$655.7K
Net activity
−$655.7K
Distinct insiders
7
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ALLO
Institutional value
$193.6M
Total shares held
81.4M
Distinct holders
110
-61 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | Pfizer Inc | 22.0M | $49.8M | +0 (+0.0%) | No change |
| 2 | BlackRock, Inc. | 19.1M | $46.6M | +1.4M (+8.0%) | Added |
| 3 | PRIMECAP MANAGEMENT CO/CA/ | 8.4M | $20.4M | +240.0K (+2.9%) | Added |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 6.9M | $16.9M | — | New |
| 5 | Candriam S.C.A. | 3.0M | $7.3M | -1.6M (-35.0%) | Trimmed |
| 6 | Wildcat Capital Management, LLC | 2.9M | $7.1M | +0 (+0.0%) | No change |
| 7 | Nuveen, LLC | 2.3M | $5.6M | +2.0M (+751.1%) | Added |
| 8 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.7M | $4.1M | — | New |
| 9 | UBS Group AG | 1.6M | $3.9M | +214.5K (+15.4%) | Added |
| 10 | abrdn plc | 1.5M | $3.6M | -624.1K (-29.9%) | Trimmed |
| 11 | JPMORGAN CHASE & CO | 1.4M | $3.2M | +455.5K (+46.5%) | Added |
| 12 | DIMENSIONAL FUND ADVISORS LP | 1.2M | $2.9M | +243.8K (+25.5%) | Added |
| 13 | VANGUARD FIDUCIARY TRUST CO | 1.1M | $2.7M | — | New |
| 14 | Invesco Ltd. | 684.5K | $1.7M | +74.7K (+12.3%) | Added |
| 15 | TD ASSET MANAGEMENT INC | 652.5K | $1.6M | +238.4K (+57.6%) | Added |
| 16 | Raiffeisen Bank International AG | 700.0K | $1.6M | -200.0K (-22.2%) | Trimmed |
| 17 | JANE STREET GROUP, LLC | 505.3K | $1.2M | -1.7M (-76.6%) | Trimmed |
| 18 | Mitsubishi UFJ Asset Management Co., Ltd. | 428.7K | $1.0M | +289.8K (+208.6%) | Added |
| 19 | Bank of New York Mellon Corp | 395.2K | $964.3K | -10.7K (-2.6%) | Trimmed |
| 20 | Creative Planning | 364.8K | $890.1K | +91.4K (+33.4%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ALLO's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.